Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allakos Inc.ALLK · Entity 79644 | Director | May 25, 2023 | May 30, 2023 |
| Esperion Therapeutics, Inc.ESPR · Entity 30796 | Director | May 27, 2021 | May 28, 2021 |
| Krystal Biotech, Inc.KRYS · Entity 3500 | Director | September 14, 2026 | September 17, 2026 |
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | Director | June 17, 2019 | June 19, 2019 |
| VIVEVE MEDICAL, INC.VIVE · Entity 11899 | Director | December 31, 2018 | January 02, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allakos Inc.
Report date May 25, 2023 · Filed May 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.81 · Expires 2033-05-25 | Direct | 86,762 |
Reported balance
After 2023-05-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-25 · Grant · Acquired 86,762 · Balance 86,762 F1: The option vests as to 100% of the shares on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of stockholders that occurs following the grant, subject to the Reporting Person continuing as a service provider through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 100% of the shares on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of stockholders that occurs following the grant, subject to the Reporting Person continuing as a service provider through each such date.
Esperion Therapeutics, Inc.
Report date May 27, 2021 · Filed May 28, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,449 |
Reported balance
After 2021-05-27 transaction · row 1
1 source rowRow 1 · 2021-05-27 · Grant · Acquired 12,376 · Balance 23,449 F1: The shares vest in full on the earlier of (i) May 27, 2022 and (ii) the Issuer's next annual meeting of stockholders following May 27, 2021. |
| Common StockSEC Table I · non-derivative | IndirectBy Alta Bioequities, L.P. | 24,565 |
Reported balance
Holding disclosure · report date 2021-05-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 24,565 F2: On February 28, 2018, Alta Partners VIII, L.P. ("APVIII") distributed 624,564 shares of Common Stock on a pro rata basis, for no additional consideration, to its partners, which distribution was exempt from Section 16 of the Exchange Act pursuant to Rule 16a-9 and Rule 16a-13. Alta Bioequities, L.P. ("Alta Bioequities") received 24,565 of these shares. Alta Bioequities Management, LLC is the general partner of Alta Bioequities L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC and may be deemed to have voting and investment power over the shares owned by Alta Bioequities, L.P. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest in full on the earlier of (i) May 27, 2022 and (ii) the Issuer's next annual meeting of stockholders following May 27, 2021.
F2: On February 28, 2018, Alta Partners VIII, L.P. ("APVIII") distributed 624,564 shares of Common Stock on a pro rata basis, for no additional consideration, to its partners, which distribution was exempt from Section 16 of the Exchange Act pursuant to Rule 16a-9 and Rule 16a-13. Alta Bioequities, L.P. ("Alta Bioequities") received 24,565 of these shares. Alta Bioequities Management, LLC is the general partner of Alta Bioequities L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC and may be deemed to have voting and investment power over the shares owned by Alta Bioequities, L.P.
Krystal Biotech, Inc.
Report date September 14, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $340.03 · Expires 2036-09-13 | Direct | 1,187 |
Reported balance
After 2026-09-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-14 · Grant · Acquired 1,187 · Balance 1,187 F1: The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. |
| Restricted Stock AwardSEC Table II · derivative / convertible security | Direct | 471 |
Reported balance
After 2026-09-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-14 · Grant · Acquired 471 · Balance 471 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F3: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.
SUTRO BIOPHARMA, INC.
Report date June 17, 2019 · Filed June 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $11.12 · Expires 2029-06-16 | Direct | 11,610 |
Reported balance
After 2019-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-17 · Grant · Acquired 11,610 · Balance 11,610 F1: The option vests as to 1/12th of the total shares monthly, beginning on July 7, 2019, with 100% of the total shares vested and exercisable on June 7, 2020, subject to the reporting person's provision of service to the issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 1/12th of the total shares monthly, beginning on July 7, 2019, with 100% of the total shares vested and exercisable on June 7, 2020, subject to the reporting person's provision of service to the issuer on each vesting date.
VIVEVE MEDICAL, INC.
Report date December 31, 2018 · Filed January 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,579 |
Reported balance
After 2018-12-31 transaction · row 1
1 source rowRow 1 · 2018-12-31 · Grant · Acquired 21,131 · Balance 60,579 F1: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received a restricted stock award of 21,131 shares of common stock on December 31, 2018 (the "Grant Date"). The restricted stock award shall vest in full on the Grant Date. |
| Common StockSEC Table I · non-derivative | IndirectSee | 1,381,955 |
Reported balance
Holding disclosure · report date 2018-12-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,381,955 F2: Directly beneficially owned by Alta Bioequities, L.P. F3: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. Daniel Janney is the Managing Director of Alta Bioequities Management, LLC and may be deemed to have voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. Each of Alta Bioequities Management, LLC and Mr. Janney disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received a restricted stock award of 21,131 shares of common stock on December 31, 2018 (the "Grant Date"). The restricted stock award shall vest in full on the Grant Date.
F2: Directly beneficially owned by Alta Bioequities, L.P.
F3: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. Daniel Janney is the Managing Director of Alta Bioequities Management, LLC and may be deemed to have voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. Each of Alta Bioequities Management, LLC and Mr. Janney disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Tyra Biosciences, Inc.
Report date September 17, 2021 · Filed September 17, 2021
Jointly reported with Alta Partners NextGen Fund II Management, LLC, Alta Partners NextGen Fund II, L.P., Hudson Peter A
Section 16 reporting ended · disclosed 2021-09-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 4,080,296 |
Last balance in matching sequence
After 2021-09-17 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2021-09-17 · Conversion · Acquired 3,811,117 · Balance 3,924,046 F1: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. As a result of the Issuer's initial public offering, the reporting persons are no longer 10% owners of the Issuer's common stock and are, therefore, no longer subject to Section 16 in connection with their transactions in the equity securities of the Issuer. F2: These securities are held directly by Alta Partners NextGen Fund II, L.P. (the "APNG II"). The shares directly held by APNG II are indirectly held by Alta Partners NextGen Fund II Management, LLC ("APNG II Management"), which is the general partner of APNG II. The individual managing directors of APNG II Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG II Management exercise shared voting and investment control with respect to the shares held by APNG II. APNG II Management, Mr. Hudson and Mr. Janney disclaim beneficial ownership of all shares held by APNG II, except to the extent of its or their respective pecuniary interests therein. Mr. More is a director of the Issuer and files separate Section 16 reports. Row 2 · 2021-09-17 · Purchase · Acquired 156,250 · Balance 4,080,296 F2: These securities are held directly by Alta Partners NextGen Fund II, L.P. (the "APNG II"). The shares directly held by APNG II are indirectly held by Alta Partners NextGen Fund II Management, LLC ("APNG II Management"), which is the general partner of APNG II. The individual managing directors of APNG II Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG II Management exercise shared voting and investment control with respect to the shares held by APNG II. APNG II Management, Mr. Hudson and Mr. Janney disclaim beneficial ownership of all shares held by APNG II, except to the extent of its or their respective pecuniary interests therein. Mr. More is a director of the Issuer and files separate Section 16 reports. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2021-09-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-09-17 · Conversion · Disposed 1,212,122 · Balance 0 F1: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. As a result of the Issuer's initial public offering, the reporting persons are no longer 10% owners of the Issuer's common stock and are, therefore, no longer subject to Section 16 in connection with their transactions in the equity securities of the Issuer. F2: These securities are held directly by Alta Partners NextGen Fund II, L.P. (the "APNG II"). The shares directly held by APNG II are indirectly held by Alta Partners NextGen Fund II Management, LLC ("APNG II Management"), which is the general partner of APNG II. The individual managing directors of APNG II Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG II Management exercise shared voting and investment control with respect to the shares held by APNG II. APNG II Management, Mr. Hudson and Mr. Janney disclaim beneficial ownership of all shares held by APNG II, except to the extent of its or their respective pecuniary interests therein. Mr. More is a director of the Issuer and files separate Section 16 reports. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2021-09-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-09-17 · Conversion · Disposed 255,160 · Balance 0 F1: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. As a result of the Issuer's initial public offering, the reporting persons are no longer 10% owners of the Issuer's common stock and are, therefore, no longer subject to Section 16 in connection with their transactions in the equity securities of the Issuer. F2: These securities are held directly by Alta Partners NextGen Fund II, L.P. (the "APNG II"). The shares directly held by APNG II are indirectly held by Alta Partners NextGen Fund II Management, LLC ("APNG II Management"), which is the general partner of APNG II. The individual managing directors of APNG II Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG II Management exercise shared voting and investment control with respect to the shares held by APNG II. APNG II Management, Mr. Hudson and Mr. Janney disclaim beneficial ownership of all shares held by APNG II, except to the extent of its or their respective pecuniary interests therein. Mr. More is a director of the Issuer and files separate Section 16 reports. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. As a result of the Issuer's initial public offering, the reporting persons are no longer 10% owners of the Issuer's common stock and are, therefore, no longer subject to Section 16 in connection with their transactions in the equity securities of the Issuer.
F2: These securities are held directly by Alta Partners NextGen Fund II, L.P. (the "APNG II"). The shares directly held by APNG II are indirectly held by Alta Partners NextGen Fund II Management, LLC ("APNG II Management"), which is the general partner of APNG II. The individual managing directors of APNG II Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG II Management exercise shared voting and investment control with respect to the shares held by APNG II. APNG II Management, Mr. Hudson and Mr. Janney disclaim beneficial ownership of all shares held by APNG II, except to the extent of its or their respective pecuniary interests therein. Mr. More is a director of the Issuer and files separate Section 16 reports.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2026 Filed Sep 17, 2026 00:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantRestricted Stock Award · Derivative | 471 | $0.00 | $0.00 |
DisclosureSEC source: 0001711279-26-000060 · wk-form4_1789603273.xml · derivative · entry 2 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 471 Underlying: Common Stock · 471 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. F3 · derivative.expiration_date: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. Read SEC document |
| September 14, 2026 Filed Sep 17, 2026 00:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 1,187 | $0.00 Strike: $340.03 | $0.00 |
DisclosureSEC source: 0001711279-26-000060 · wk-form4_1789603273.xml · derivative · entry 1 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,187 Underlying: Common Stock · 1,187 shares Expires 2036-09-13 F1 · derivative.exercise_date: The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:28 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,373 | $276.17 | $655,343.10 |
DisclosureSEC source: 0001711279-26-000023 · wk-form4_1772580519.xml · nonDerivative · entry 2 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 73,293 F1 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. F4 · price: The transaction was executed in multiple trades ranging from $276 to $276.4924. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F3 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:28 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 9,430 | $275.45 | $2,597,481.24 |
DisclosureSEC source: 0001711279-26-000023 · wk-form4_1772580519.xml · nonDerivative · entry 1 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 75,666 F1 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. F2 · price: The transaction was executed in multiple trades ranging from $275 to $275.986. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F3 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| February 26, 2026 Filed Feb 26, 2026 23:49 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,638 | $276.32 | $728,919.50 |
DisclosureSEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 21 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 85,096 F11 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. F23 · price: The transaction was executed in multiple trades ranging from $276 to $276.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F13 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| February 26, 2026 Filed Feb 26, 2026 23:49 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 5,103 | $275.28 | $1,404,759.96 |
DisclosureSEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 20 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 87,734 F11 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. F22 · price: The transaction was executed in multiple trades ranging from $275 to $275.9782. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F13 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 23:49 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 700 | $275.00 | $192,500.00 |
DisclosureSEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 19 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 92,837 F11 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. F21 · price: The transaction was executed in a single trade. F13 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:49 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionStock Option (Right to Buy) · Derivative | 37,895 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · derivative · entry 22 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,895 shares Expires 2026-11-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. F24 · derivative.exercise_date: The options vested ratably over a four-year period beginning on November 10, 2016. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:49 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,425 | $274.90 | $666,626.92 |
DisclosureSEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 18 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 93,537 F11 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. F20 · price: The transaction was executed in multiple trades ranging from $274.59 to $275. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F13 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:49 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 930 | $269.50 | $250,636.21 |
DisclosureSEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 17 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 95,962 F11 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. F19 · price: The transaction was executed in multiple trades ranging from $269.1641 to $269.78. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F13 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:49 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,674 | $268.67 | $449,746.88 |
DisclosureSEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 16 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 96,892 F11 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. F18 · price: The transaction was executed in multiple trades ranging from $268.0725 to $269.0705. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F13 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:49 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,891 | $267.37 | $505,596.67 |
DisclosureSEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 15 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 98,566 F11 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. F17 · price: The transaction was executed in multiple trades ranging from $267.0631 to $268.0275. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F13 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:49 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 4,339 | $266.62 | $1,156,878.93 |
DisclosureSEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 14 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 100,457 F11 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. F16 · price: The transaction was executed in multiple trades ranging from $266.06 to $267.0511. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F13 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:49 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,604 | $265.54 | $425,919.10 |
DisclosureSEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 13 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 104,796 F11 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. F15 · price: The transaction was executed in multiple trades ranging from $265.04 to $266. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F13 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:49 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 900 | $264.60 | $238,136.04 |
DisclosureSEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 12 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 106,400 F11 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. F14 · price: The transaction was executed in multiple trades ranging from $264.01 to $264.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F13 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:49 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 62 | $263.05 | $16,309.17 |
DisclosureSEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 11 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 107,300 F11 · kind: The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. F12 · price: The transaction was executed in multiple trades ranging from $262.9496 to $263.1269. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F13 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:49 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 373 | $271.09 | $101,117.99 |
DisclosureSEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 10 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F10 · price: The transaction was executed in multiple trades ranging from $270.650 to $271.610. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:49 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 370 | $269.83 | $99,836.43 |
DisclosureSEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 9 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 373 F9 · price: The transaction was executed in multiple trades ranging from $269.610 to $270.140. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:49 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 3,963 | $268.97 | $1,065,923.75 |
DisclosureSEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 8 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 743 F8 · price: The transaction was executed in multiple trades ranging from $268.540 to $269.530. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:49 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 6,671 | $268.04 | $1,788,079.50 |
DisclosureSEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 7 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,706 F7 · price: The transaction was executed in multiple trades ranging from $267.520 to $268.510. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:49 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 11,673 | $266.97 | $3,116,310.46 |
DisclosureSEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 6 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,377 F6 · price: The transaction was executed in multiple trades ranging from $266.520 to $267.510. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:49 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 8,986 | $266.18 | $2,391,885.39 |
DisclosureSEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 5 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,050 F5 · price: The transaction was executed in multiple trades ranging from $265.520 to $266.510. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:49 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 3,557 | $265.08 | $942,878.18 |
DisclosureSEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 4 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,036 F4 · price: The transaction was executed in multiple trades ranging from $264.520 to $265.495. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:49 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,733 | $264.12 | $457,727.93 |
DisclosureSEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 3 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,593 F3 · price: The transaction was executed in multiple trades ranging from $263.510 to $264.450. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:49 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 569 | $262.91 | $149,594.08 |
DisclosureSEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 2 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,326 F2 · price: The transaction was executed in multiple trades ranging from $262.480 to $263.400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:49 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 37,895 | $2.46 | $93,221.70 |
DisclosureSEC source: 0001711279-26-000021 · wk-form4_1772149785.xml · nonDerivative · entry 1 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. Read SEC document |
| June 30, 2025 Filed Jun 30, 2025 22:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $137.46 | $0.00 |
DisclosureSEC source: 0001711279-25-000057 · wk-form4_1751321689.xml · derivative · entry 1 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2035-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2025 and vest in equal monthly tranches over a one-year period. Read SEC document |
| June 30, 2024 Filed Jul 1, 2024 23:34 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $183.64 | $0.00 |
DisclosureSEC source: 0001711279-24-000029 · wk-form4_1719876885.xml · derivative · entry 1 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2024 and vest in equal monthly tranches over a one-year period. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 6,800 | $0.00 Strike: $117.40 | $0.00 |
DisclosureSEC source: 0001711279-23-000051 · wk-form4_1688415647.xml · derivative · entry 1 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Stock · 6,800 shares Expires 2033-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2023 and vest in equal monthly tranches over a one-year period. Read SEC document |
| June 09, 2023 Filed Jun 9, 2023 23:03 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 10,000 | $128.53 | $1,285,262.00 |
DisclosureSEC source: 0001711279-23-000046 · wk-form4_1686351820.xml · nonDerivative · entry 9 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 107,362 F7 · price: The transaction was executed in multiple trades ranging from $127.715 to $129.6100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F1 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 09, 2023 Filed Jun 9, 2023 23:03 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 5,000 | $128.84 | $644,187.50 |
DisclosureSEC source: 0001711279-23-000046 · wk-form4_1686351820.xml · nonDerivative · entry 8 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 117,362 F6 · price: The transaction was executed in multiple trades ranging from $128.5000 to $129.4800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F1 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 09, 2023 Filed Jun 9, 2023 23:03 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 3,935 | $129.29 | $508,773.07 |
DisclosureSEC source: 0001711279-23-000046 · wk-form4_1686351820.xml · nonDerivative · entry 7 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 122,362 F5 · price: The transaction was executed in multiple trades ranging from $129.0000 to $129.7400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F1 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 23:03 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 5,000 | $127.86 | $639,306.00 |
DisclosureSEC source: 0001711279-23-000046 · wk-form4_1686351820.xml · nonDerivative · entry 6 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 126,297 F4 · price: The transaction was executed in multiple trades ranging from $127.7000 to $128.44. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F1 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 23:03 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 10,000 | $127.96 | $1,279,584.00 |
DisclosureSEC source: 0001711279-23-000046 · wk-form4_1686351820.xml · nonDerivative · entry 5 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 131,297 F1 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 23:03 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 5,000 | $127.96 | $639,790.00 |
DisclosureSEC source: 0001711279-23-000046 · wk-form4_1686351820.xml · nonDerivative · entry 4 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 141,297 F1 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 23:03 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 5,388 | $128.73 | $693,616.10 |
DisclosureSEC source: 0001711279-23-000046 · wk-form4_1686351820.xml · nonDerivative · entry 3 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 146,297 F3 · price: The transaction was executed in multiple trades ranging from $128.5000 to $129.0600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F1 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 23:03 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,073 | $129.02 | $138,440.39 |
DisclosureSEC source: 0001711279-23-000046 · wk-form4_1686351820.xml · nonDerivative · entry 2 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 151,685 F2 · price: The transaction was executed in multiple trades ranging from $129.0000 to $129.0600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F1 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 23:03 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 4,604 | $127.96 | $589,117.71 |
DisclosureSEC source: 0001711279-23-000046 · wk-form4_1686351820.xml · nonDerivative · entry 1 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 152,758 F1 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| May 25, 2023 Filed May 30, 2023 18:00 UTC | Allakos Inc. ALLK · Entity 79644 | GrantStock Option (Right to buy) · Derivative | 86,762 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001209191-23-032970 · doc4.xml · derivative · entry 1 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,762 Underlying: Common Stock · 86,762 shares Expires 2033-05-25 F1 · derivative.exercise_date: The option vests as to 100% of the shares on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of stockholders that occurs following the grant, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 19, 2023 Filed May 23, 2023 20:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 50,000 | $95.02 | $4,751,185.00 |
DisclosureSEC source: 0001711279-23-000042 · wf-form4_168487321853185.xml · nonDerivative · entry 1 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 157,362 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 12, 2022 and will terminate on September 11, 2023 and contemplates sales of 50,000 shares with a limit price of $95.00 per share. F2 · price: The transaction was executed in multiple trades ranging from $95.0000 to $95.3800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F3 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| May 09, 2023 Filed May 11, 2023 20:30 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 17,100 | $90.74 | $1,551,578.76 |
DisclosureSEC source: 0001711279-23-000035 · wf-form4_168383702435561.xml · nonDerivative · entry 1 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 207,362 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 12, 2022 and will terminate on September 11, 2023 and contemplates sales of 25,000 shares with a limit price of $90.00 per share. F2 · price: The transaction was executed in multiple trades ranging from $90.0000 to $91.1350. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F3 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| April 19, 2023 Filed Apr 21, 2023 20:10 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 7,900 | $90.32 | $713,493.24 |
DisclosureSEC source: 0001711279-23-000023 · wf-form4_168210784238261.xml · nonDerivative · entry 1 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Directly beneficially owned by Alta Bioequities, L.P. Disclosed balance after: 224,462 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 12, 2022 and will terminate on September 11, 2023 and contemplates sales of 25,000 shares with a limit price of $90.00 per share. F2 · price: The transaction was executed in multiple trades ranging from $90.0000 to $90.3650. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F3 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 21, 2022 Filed Sep 23, 2022 16:25 UTC | Allakos Inc. ALLK · Entity 79644 | PurchaseCommon Stock | 475,000 | $5.02 | $2,384,500.00 |
DisclosureSEC source: 0001209191-22-051141 · doc4.xml · nonDerivative · entry 1 JANNEY DANIEL · CIK 0001198325 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Alta Partners NextGen Fund I, L.P. Disclosed balance after: 2,546,147 F1 · kind: Reports the purchase of shares in the underwritten public offering of common stock of the Issuer. F2 · ownership.nature: The shares are directly held by Alta Partners NextGen Fund I, L.P. ("APNG I"). Alta Partners NextGen Fund I Management, LLC ("APNG I Management") is the general partner of APNG I. The Reporting Person is one of three managing directors of APNG I Management and, as such, has voting and investment control with respect to the shares held by APNG I. The Reporting Person disclaims beneficial ownership of all shares held by APNG I, except to the extent of his pecuniary interest therein. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:12 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 6,800 | $0.00 Strike: $65.66 | $0.00 |
DisclosureSEC source: 0001711279-22-000038 · wf-form4_165670631803960.xml · derivative · entry 1 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Stock · 6,800 shares Expires 2032-06-30 F1 · derivative.exercise_date: The options were awarded on June 30, 2022 and vest in equal monthly tranches over a one-year period. Read SEC document |
| May 25, 2022 Filed May 27, 2022 16:16 UTC | Allakos Inc. ALLK · Entity 79644 | GrantStock Option (Right to buy) · Derivative | 99,590 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001209191-22-032520 · doc4.xml · derivative · entry 1 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,590 Underlying: Common Stock · 99,590 shares Expires 2032-05-25 F1 · derivative.exercise_date: The option vests as to 100% of the shares on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of stockholders that occurs following the grant, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 30, 2021 Filed Feb 2, 2022 21:38 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GiftCommon Stock | 34,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-002225 · form5.xml · nonDerivative · entry 1 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,362 F1 · shares: The Reporting Person transferred these shares of common stock to a charitable trust, over which the Reporting Person has no pecuniary interest or investment control. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 21:11 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 100,000 | $70.50 | $7,050,000.00 |
DisclosureSEC source: 0000899243-21-048122 · doc4.xml · nonDerivative · entry 1 JANNEY DANIEL · CIK 0001198325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Alta Bioequities L.P Disclosed balance after: 266,362 F1 · shares: On December 3, 2021, Krystal Biotech, Inc. (the "Company"), closed the previously announced underwritten public offering of 2,666,667 shares of its common stock, at a public offering price of $75.00 per share. The Company and certain selling stockholders granted the underwriters a 30-day option to purchase up to an additional 400,000 shares of the Company's common stock offered in the public offering, which includes up to 200,000 shares from the selling stockholders. The underwriters exercised the option and on December 10, 2021, purchased the 400,000 shares of the Company's common stock, including 100,000 shares of the Company's common stock from Alta Bioequities, L.P., a selling stockholder. F2 · ownership.nature: Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC and may be deemed to have voting and investment power over the shares owned by Alta Bioequities, L.P. Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 20:47 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionSeries B Preferred Stock · Derivative | 255,160 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036429 · doc4.xml · derivative · entry 4 Alta Partners NextGen Fund II Management, LLC · CIK 0001881002 · 10% owner Alta Partners NextGen Fund II, L.P. · CIK 0001768658 · 10% owner Hudson Peter A · CIK 0001674884 · 10% owner JANNEY DANIEL · CIK 0001198325 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 662,752 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. As a result of the Issuer's initial public offering, the reporting persons are no longer 10% owners of the Issuer's common stock and are, therefore, no longer subject to Section 16 in connection with their transactions in the equity securities of the Issuer. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. As a result of the Issuer's initial public offering, the reporting persons are no longer 10% owners of the Issuer's common stock and are, therefore, no longer subject to Section 16 in connection with their transactions in the equity securities of the Issuer. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. As a result of the Issuer's initial public offering, the reporting persons are no longer 10% owners of the Issuer's common stock and are, therefore, no longer subject to Section 16 in connection with their transactions in the equity securities of the Issuer. F2 · ownership.nature: These securities are held directly by Alta Partners NextGen Fund II, L.P. (the "APNG II"). The shares directly held by APNG II are indirectly held by Alta Partners NextGen Fund II Management, LLC ("APNG II Management"), which is the general partner of APNG II. The individual managing directors of APNG II Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG II Management exercise shared voting and investment control with respect to the shares held by APNG II. APNG II Management, Mr. Hudson and Mr. Janney disclaim beneficial ownership of all shares held by APNG II, except to the extent of its or their respective pecuniary interests therein. Mr. More is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 20:47 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionSeries A Preferred Stock · Derivative | 1,212,122 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036429 · doc4.xml · derivative · entry 3 Alta Partners NextGen Fund II Management, LLC · CIK 0001881002 · 10% owner Alta Partners NextGen Fund II, L.P. · CIK 0001768658 · 10% owner Hudson Peter A · CIK 0001674884 · 10% owner JANNEY DANIEL · CIK 0001198325 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 3,148,365 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. As a result of the Issuer's initial public offering, the reporting persons are no longer 10% owners of the Issuer's common stock and are, therefore, no longer subject to Section 16 in connection with their transactions in the equity securities of the Issuer. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. As a result of the Issuer's initial public offering, the reporting persons are no longer 10% owners of the Issuer's common stock and are, therefore, no longer subject to Section 16 in connection with their transactions in the equity securities of the Issuer. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. As a result of the Issuer's initial public offering, the reporting persons are no longer 10% owners of the Issuer's common stock and are, therefore, no longer subject to Section 16 in connection with their transactions in the equity securities of the Issuer. F2 · ownership.nature: These securities are held directly by Alta Partners NextGen Fund II, L.P. (the "APNG II"). The shares directly held by APNG II are indirectly held by Alta Partners NextGen Fund II Management, LLC ("APNG II Management"), which is the general partner of APNG II. The individual managing directors of APNG II Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG II Management exercise shared voting and investment control with respect to the shares held by APNG II. APNG II Management, Mr. Hudson and Mr. Janney disclaim beneficial ownership of all shares held by APNG II, except to the extent of its or their respective pecuniary interests therein. Mr. More is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 20:47 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | PurchaseCommon Stock | 156,250 | $16.00 | $2,500,000.00 |
DisclosureSEC source: 0000899243-21-036429 · doc4.xml · nonDerivative · entry 2 Alta Partners NextGen Fund II Management, LLC · CIK 0001881002 · 10% owner Alta Partners NextGen Fund II, L.P. · CIK 0001768658 · 10% owner Hudson Peter A · CIK 0001674884 · 10% owner JANNEY DANIEL · CIK 0001198325 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,080,296 F2 · ownership.nature: These securities are held directly by Alta Partners NextGen Fund II, L.P. (the "APNG II"). The shares directly held by APNG II are indirectly held by Alta Partners NextGen Fund II Management, LLC ("APNG II Management"), which is the general partner of APNG II. The individual managing directors of APNG II Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG II Management exercise shared voting and investment control with respect to the shares held by APNG II. APNG II Management, Mr. Hudson and Mr. Janney disclaim beneficial ownership of all shares held by APNG II, except to the extent of its or their respective pecuniary interests therein. Mr. More is a director of the Issuer and files separate Section 16 reports. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.